XTL Biopharmaceuticals has entered into a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. NeuroNOS focuses on developing disease-modifying therapeutics for Autism Spectrum Disorder (ASD) and neuro-oncology, targeting the core biology of autism rather than just providing symptomatic relief. As part of the transaction, Beyond Air will retain a 19.99% stake in XTL’s post-transaction share capital and may receive up to $32.5 million in upfront, development, and commercial milestone payments. The deal brings together a scientific team that includes two Nobel Laureates and Professor Haitham Amal, with the aim of advancing innovative treatments for autism and related conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beyond Air Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-002292), on January 15, 2026, and is solely responsible for the information contained therein.